CBIOCRESCENT BIOPHARMA, INC.
Pharmaceutical Preparations
- Revenue
- $11M
- Operating margin
- -1407.5%
- EBITDA
- −$153M
- 281% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 2 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired-465× net incomeCash flow under 80% of net income
- Dilutive SBCFired123% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1M | $75K | $10K | — | $11M | |
| Operating income | −$63M | −$47M | −$39M | −$40M | −$153M | 281% |
| Net income | −$63M | −$47M | $37K | $38K | $154K | 306% |
| Operating cash flow | −$57M | −$46M | −$35M | −$31M | −$72M | 130% |
| Capex | $15K | $84K | $21K | $10K | $919K | 9116% |
| Stock-based comp | $6M | $4M | $4M | $5M | $13M | 183% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $13M | $18M | 4 | — |
| FY2024 | — | — | 8 | — |
| FY2023 | — | — | 78 | — |